Description
Indications
- Early-stage estrogen receptor-expressing breast cancer in postmenopausal women – as adjuvant therapy
- Early-stage breast cancer in postmenopausal women after completion of standard adjuvant tamoxifen therapy – as extended adjuvant therapy
- Advanced hormone-dependent breast cancer in postmenopausal women – first-line therapy
- advanced breast cancer in postmenopausal women (natural or artificially induced) who have received prior anti-estrogen therapy
Contraindications
- Endocrine status characteristic of the reproductive period.
- pregnancy . – period of lactation (breastfeeding).
- infancy (efficacy and safety in children has not been established).
- hypersensitivity to the drug components. The drug should be used with caution in lactase deficiency, lactase intolerance, glucose-galactose malabsorption. There are no data on the use of Letrozole in patients with CK less than 30 ml/min (before prescribing the drug to such patients, the ratio between the potential risk and expected effect of treatment should be carefully weighed).
Use in pregnancy and lactation
Use is contraindicated in pregnancy and during lactation (breastfeeding).
Reviews
There are no reviews yet.